Clinical Trial Update: Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias [Phase 1]

View source ↗

Summary

A Phase 1 trial completed evaluating the safety, tolerability, and preliminary efficacy of BKM120 (buparlisib), a PI3K inhibitor, in patients with advanced leuk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• BKM120 (Buparlisib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 1 | Status: COMPLETED